Non-valuvular atrial fibrillation (NVAF) is common among the elderly; with> 50% NVAF
patients being> _80 years of age. 1 Despite this fact, patients> _80 years of age are often …

Introduction: More than half of patients with nonvalvular atrial fibrillation (NVAF) are≥ 80
years of age; yet such patients are often underrepresented in studies of oral anticoagulation …

Results From July 2013 to December 2015, 137.800 individuals on oral anticoagulant
treatment were identified (Fig. 1). Of these, 22.896 were excluded for indications other than …

Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial,
demonstrating safety in the Asian population. It remains unclear whether treatment with …

Background: The J-ROCKET AF study found that rivaroxaban was non-inferior to warfarin
with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of …

Background Establishing the appropriate rivaroxaban dose in older patients with non-
valvular atrial fibrillation (NVAF) is important because of the high risk of adverse events. In …

Background—Nonvalvular atrial fibrillation is common in elderly patients, who face an
elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor …

Direct oral anticoagulants (DOACs), such as rivaroxaban, reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). However, it is still …

Aims The real-life benefits and risks of the non-vitamin K antagonist oral anticoagulants for
stroke prevention in very elderly patients with atrial fibrillation (AF) are still debated. Methods …

Objective Direct oral anticoagulants have been evaluated in the general population, but
proper evidence for their safe use in the geriatric population is still missing. We compared …